A new fiducial marker for Image-guided radiotherapy of prostate cancer: Clinical experience

References

• Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, et al. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 2005; 61: 993–1002
   PubMed Web of Science ®Google Scholar
• Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 2005; 61: 415–9
   PubMed Web of Science ®Google Scholar
• Cheung MR. The need and prospect of individualized external beam radiotherapy dose escalation beyond 80 Gy to treat prostate cancer: In regard to Eade et al. (Int J Radiat Oncol Biol Phys 2007;68:682–9). Int J Radiat Oncol Biol Phys 2008; 70: 645–6
   PubMedGoogle Scholar
• Michalski JM, Purdy JA, Winter K, Roach M, III, Vijayakumar S, Sandler HM, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 2000; 46: 391–402
   PubMed Web of Science ®Google Scholar
• Bey P, Carrie C, Beckendorf V, Ginestet C, Aletti P, Madelis G, et al. Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal 3D radiotherapy in prostate cancer – Preliminary results. Int J Radiat Oncol Biol Phys 2000; 48: 513–7
   PubMedGoogle Scholar
• Boersma LJ, van den BM, Bruce AM, Shouman T, Gras L, te VA, et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70–78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 1998; 41: 83–92
   PubMed Web of Science ®Google Scholar
• Teh BS, Mai WY, Grant WH, III, Chiu JK, Lu HH, Carpenter LS, et al. Intensity modulated radiotherapy (IMRT) decreases treatment-related morbidity and potentially enhances tumor control. Cancer Invest 2002; 20: 437–51
   PubMed Web of Science ®Google Scholar
• Zhang M, Moiseenko V, Liu M, Craig T. Internal fiducial markers can assist dose escalation in treatment of prostate cancer: Result of organ motion simulations. Phys Med Biol 2006; 51: 269–85
   PubMed Web of Science ®Google Scholar
• Crook JM, Raymond Y, Salhani D, Yang H, Esche B. Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol 1995; 37: 35–42
   PubMed Web of Science ®Google Scholar
• Kitamura K, Shirato H, Shimizu S, Shinohara N, Harabayashi T, Shimizu T, et al. Registration accuracy and possible migration of internal fiducial gold marker implanted in prostate and liver treated with real-time tumor-tracking radiation therapy (RTRT). Radiother Oncol 2002; 62: 275–81
   PubMed Web of Science ®Google Scholar
• Vigneault E, Pouliot J, Laverdiere J, Roy J, Dorion M. Electronic portal imaging device detection of radioopaque markers for the evaluation of prostate position during megavoltage irradiation: A clinical study. Int J Radiat Oncol Biol Phys 1997; 37: 205–12
   PubMed Web of Science ®Google Scholar
• Carl J, Lund B, Larsen EH, Nielsen J. Feasibility study using a Ni-Ti stent and electronic portal imaging to localize the prostate during radiotherapy. Radiother Oncol 2006; 78: 199–206
   PubMed Web of Science ®Google Scholar
• Carl J, Nielsen H, Nielsen J, Lund B, Larsen EH. Automated detection of a prostate Ni-Ti stent in electronic portal images. Med Phys 2006; 33: 4600–5
   PubMedGoogle Scholar
• Perry MJ, Roodhouse AJ, Gidlow AB, Spicer TG, Ellis BW. Thermo-expandable intraprostatic stents in bladder outlet obstruction: An 8-year study. BJU Int 2002; 90: 216–23
   PubMed Web of Science ®Google Scholar
• Rasch C, Barillot I, Remeijer P, Touw A, van HM, Lebesque JV. Definition of the prostate in CT and MRI: A multi-observer study. Int J Radiat Oncol Biol Phys 1999; 43: 57–66
   PubMed Web of Science ®Google Scholar
• Kotte AN, Hofman P, Lagendijk JJ, van VM, van der Heide UA. Intrafraction motion of the prostate during external-beam radiation therapy: Analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys 2007; 69: 419–25
   PubMed Web of Science ®Google Scholar
• Linthout N, Verellen D, Tournel K, Reynders T, Duchateau M, Storme G. Assessment of secondary patient motion induced by automated couch movement during on-line 6 dimensional repositioning in prostate cancer treatment. Radiother Oncol 2007; 83: 168–74
   PubMed Web of Science ®Google Scholar
• Singh AK, Guion P, Sears-Crouse N, Ullman K, Smith S, Albert PS, et al. Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: Early results of a phase I NCI study. Radiat Oncol 2007; 2: 36
   PubMed Web of Science ®Google Scholar
• van Lin EN, Futterer JJ, Heijmink SW, van d V, Hoffmann AL, van KP, et al. IMRT boost dose planning on dominant intraprostatic lesions: Gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 2006; 65: 291–303
   PubMed Web of Science ®Google Scholar